Kayentis, a global provider of eCOA solutions for clinical trials headquartered in France, has announced the launch of a set of initiatives to evaluate the carbon footprint of each clinical trial services eCOA component it conducts and propose solutions to clients on limiting the CO2 emissions of these eCOA projects.
Guillaume Juge, CEO of Kayentis. “While the solutions to reduce the impact of carbon emissions require closer collaboration with our customers, they have no impact on the cost of the study, nor will they lessen the quality or timeliness of the service we provide.” Some eCOA options, depending on the protocol include:
For more information click here.
‘Hypothesis-Free’: Getting Proactive About Signal Detection
December 5th 2023Elizabeth Smalley, director of product management, data, and analytics at ArisGlobal speaks about her work at the software company in supporting the efforts of life sciences clinical and pharmacovigilance teams in signal detection.